

Study: *Pseudomyxoma Peritonei: Prognostic Analysis of Micro-RNA and Other Biologic Factors Using Tissue Microarray*

Marcello Deraco, MD

Fondazione IRCCS Istituto Nazionale Tumore
Milan, Italy

Markers related to the origin and peculiar clinical features of PMP are being investigated, using tissue micro arrays (TMA) in tumour samples from a set of 160 patients operated on at our centre up to May, 2011. Such markers will be correlated with patient's survival. Our intention is to identify dysregulated micro-RNAs in PMP, and to assess whether they act as key players in disease progression by analyzing their association with patients' prognosis. *At the time of this interim report the TMA have been built.*

The potential prognostic factors identified through the retrospective analysis will be prospectively validated. Approximately 50 patients are expected to be treated at our centre during this 2-year study period. The study end-point is progression-free survival, since PMP generally shows a prolonged clinical course.

At the time of this interim report, 22 patients have been enrolled in the study. All patients received a radical treatment with CRS (macroscopic surgical cyto-reduction) and HIPEC.